ScanTech AI 2025 Q2 Earnings Narrowed Losses by 63.6% Despite Wider Net Loss

ScanTech AI (STAI) reported fiscal 2025 Q2 results on Nov 28, 2025, with revenue surging 69.3% year-over-year to $883.97 million. The company narrowed its per-share loss to $0.16 from $0.44, marking a 63.6% improvement. However, the net loss widened to $6.94 million, reflecting ongoing operational challenges. While the earnings report highlights progress in cost management, the lack of explicit guidance and persistent losses underscore near-term risks for investors.

Revenue

ScanTech AI’s total revenue rose sharply to $883.97 million in Q2 2025, a 69.3% increase from $522.17 million in the same period the prior year. This growth was driven by robust demand for AI-driven diagnostic solutions in healthcare and industrial sectors, as noted by CEO John Carter.

Earnings/Net Income

The company reduced its per-share loss to $0.16 in Q2 2025 from $0.44 in Q2 2024, a 63.6% improvement. However, the net loss expanded to $6.94 million, a 21.6% increase from $5.71 million a year earlier. Despite the per-share loss narrowing, the overall net loss widened, indicating mixed profitability outcomes.

Price Action

The stock price of ScanTech AI climbed 4.35% on the latest trading day, surged 13.21% over the past week, but fell 28.85% month-to-date.

Post-Earnings Price Action Review

The strategy of buying ScanTech AI shares 30 days after its revenue-aligned quarter report has performed poorly over the past three years, with a CAGR of -81.79%, total return of -60.11%, and excess return of -74.78%. The strategy’s maximum drawdown of 0.00% and Sharpe ratio of -0.60 highlight its high risk and consistent losses, suggesting caution for investors relying on post-earnings timing.

CEO Commentary

CEO John Carter emphasized growth in AI diagnostics but acknowledged rising R&D costs and supply chain disruptions. He outlined plans to accelerate cloud-based AI platforms and optimize costs while targeting EBITDA breakeven by mid-2026.

Guidance

ScanTech AI did not provide explicit 2025 guidance but aims for a 15% year-over-year revenue growth in core AI diagnostics. The company also plans to reduce non-essential CAPEX by 10% in 2025.

Additional News

ScanTech AI filed restated Q1 2025 and reviewed Q2 2025 financials under new auditor Berkowitz Pollack Brant, a critical step in its Nasdaq compliance efforts. The company also announced a strategic partnership with Germany’s unival group to expand AI security systems in Europe, the Middle East, and Africa. Additionally, it inked a non-binding term sheet for a $20 million convertible note facility, offering $6 million upfront upon regulatory approval. These moves aim to strengthen market access and secure liquidity amid ongoing financial challenges.

Image suggestion: A graph showing ScanTech AI’s stock price volatility over the past month, juxtaposed with its revenue growth and net loss trends.